Last updated: 11/07/2018 16:56:23
A double-blind, randomized, placebo-controlled study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a six-month open-label safety extension in subjects with perennial nonallergic rhinitis
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A double-blind, randomized, placebo-controlled study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a six-month open-label safety extension in subjects with perennial nonallergic rhinitis
Trial description: A double-blind, randomized, placebo-controlled study of the efficacy and safety of fluticasone propionate aqueous nasal spray versus placebo followed by a six-month open-label safety extension in subjects with perennial nonallergic rhinitis
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Finn AF, Howland WC, Bronsky EA, Lumry WR, Pepsin PJ, Rogenes PR, Westlund R, Cook CK. Efficacy of three different dosing regimens of fluticasone propionate (FP) aqueous nasal spray in the treatment of perennial nonallergic rhinitis (PNAR). Allergy Clin Immunol 1997;99(No. 1, Part 2):S440 (abstract)
Pepsin PJ, Howland WC, Finn AF, Cox FM, Bowers BW, Montgomery E, Westlund R. Patient-rated overall treatment satisfaction and effectiveness with three dosing regimens of intranasal fluticasone propionate (FP) in perennial nonallergic rhinitis (PNAR). J Allergy Clin Immunol 1997;99(No. 1, Part 2):S442
Picone FJ, Pepsin PJ, Westlund R, Rogenes PR, Cook CK. Intranasal fluticasone propionate (FP) is effective in patients with perennial non-allergic rhinitis (NARES or Non-NARES). Ann of Allergy, Asthma, and Immunol 1998;80(1):111 (abstract)
Medical condition
Rhinitis, Allergic, Perennial
Product
fluticasone propionate
Collaborators
Not applicable
Study date(s)
December 1995 to May 1996
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1996-01-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website